1.02
+0.1998(+24.36%)
Currency In USD
| Previous Close | 0.82 |
| Open | 0.79 |
| Day High | 1.02 |
| Day Low | 0.75 |
| 52-Week High | 2.79 |
| 52-Week Low | 0.32 |
| Volume | 8.06M |
| Average Volume | 5.93M |
| Market Cap | 67.2M |
| PE | -0.65 |
| EPS | -1.58 |
| Moving Average 50 Days | 1.33 |
| Moving Average 200 Days | 1.23 |
| Change | 0.2 |
If you invested $1000 in IO Biotech, Inc. (IOBT) since IPO date, it would be worth $65.18 as of October 22, 2025 at a share price of $1.02. Whereas If you bought $1000 worth of IO Biotech, Inc. (IOBT) shares 3 years ago, it would be worth $435.9 as of October 22, 2025 at a share price of $1.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
GlobeNewswire Inc.
Oct 20, 2025 6:30 AM GMT
Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS) primary endpoint for statistic
IO Biotech Provides Update Following Pre-BLA Meeting with FDA
GlobeNewswire Inc.
Sep 29, 2025 11:05 AM GMT
FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data from the IOB-013 clinical trial Company plans to design new registrational study for Cylembio for the treatment of first-line patients with advanced mel
IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025
GlobeNewswire Inc.
Sep 23, 2025 12:05 PM GMT
Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanomaPoster presentation will share final data from Phase 2 basket trial